AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18562775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI/Low-GL meal (L-L) - Carbohydrate content 65%, GI 40, GL 42
Number of subjects: 8
Study 18562775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI/Low-GL meal (H-L) - Carbohydrate content 36%, GI 78, GL 44
Number of subjects: 8
Study 18562775 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 18401016 — intervention group
Group type: EXPERIMENTAL
Intervention: 852A 0.01%
Number of subjects: 32
Study 18401016 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 32
Study 18401016 — intervention group
Group type: EXPERIMENTAL
Intervention: 852A 0.1%
Number of subjects: 32
Study 18401016 — intervention group
Group type: EXPERIMENTAL
Intervention: 852A 0.3%
Number of subjects: 32
Study 18401016 — intervention group
Group type: EXPERIMENTAL
Intervention: 852A 1.0%
Number of subjects: 32
Study 12972438 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 13
Study 12972438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 13
Study 11300437 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hospital stay (3 days)
Number of subjects: 120
Study 11300437 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital stay
Number of subjects: 120
Study 9075595 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor-based treatment
Number of subjects: 6000
Study 9075595 — intervention group
Group type: COMPARATOR
Intervention: Diuretic-based treatment
Number of subjects: 6000
Study 8104964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 0
Study 8104964 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0
Study 8104964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3530834 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ciclopirox olamine cream
Number of subjects: 0
Study 3530834 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clotrimazole cream
Number of subjects: 0
Study 3530834 — intervention group
Group type: COMPARATOR
Intervention: Cream vehicle
Number of subjects: 0
Study 28301438 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week low-volume high-intensity interval training (HIIT)
Number of subjects: 90
Study 28301438 — intervention group
Group type: COMPARATOR
Intervention: Low-moderate-intensity continuous training (Control Group)
Number of subjects: 90
Study 29874567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 0
Study 29874567 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiome transplantation from mice on IF
Number of subjects: 0
Study 27329657 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg intravenous at 0, 2, and 6 weeks)
Number of subjects: 270
Study 27329657 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (2 mg/kg/day intravenous for 7 days followed by 5.5 mg/kg/day oral until 12 weeks)
Number of subjects: 270
Study 27329657 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 270
Study 27329657 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 270
Study 24576533 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1mg/kg)
Number of subjects: 263
Study 24576533 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (various)
Number of subjects: 263
Study 24576533 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 263
Study 22105061 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine therapy in an opioid treatment program (OTP) with individual counseling
Number of subjects: 0
Study 22105061 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine therapy in a group counseling program utilizing the Matrix Model (MMM)
Number of subjects: 0
Study 22105061 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine therapy in a private clinic setting mirroring standard medical management
Number of subjects: 0
Study 22105061 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine treatment
Number of subjects: 0
Study 19757225 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual imagery technique
Number of subjects: 153
Study 19757225 — intervention group
Group type: COMPARATOR
Intervention: Active control (relaxation training and general imagery techniques)
Number of subjects: 153
Study 19757225 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 153
Study 17452229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent mandatory ventilation (NIMV)
Number of subjects: 84
Study 17452229 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 84
Study 15768813 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/l topical amphotericin B
Number of subjects: 41
Study 15768813 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/l topical amphotericin B
Number of subjects: 41
Study 15768813 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41
Study 11486703 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF)
Number of subjects: 207
Study 11486703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 9738066 — intervention group
Group type: EXPERIMENTAL
Intervention: BHI-VAN broth (brain heart infusion broth, horse serum, and yeast extract supplemented with vancomycin, amphotericin B, and nalidixic acid)
Number of subjects: 254
Study 7809438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 53
Study 7809438 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 53
Study 3046382 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐adenosylmethionine
Number of subjects: 18
Study 3046382 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (low oral doses)
Number of subjects: 18
Study 30521521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multifaceted implementation strategy (local action planning, education and training, feedback on performance, lumbar puncture pack, optional components)
Number of subjects: 489
Study 30521521 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 489
Study 30521521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups (pre-intervention comparison)
Number of subjects: 489
Study 27611311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) patches
Number of subjects: 1050
Study 27611311 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study 25624196 — intervention group
Group type: EXPERIMENTAL
Intervention: Long GnRH agonist cycles
Number of subjects: 1205
Study 25624196 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist cycles
Number of subjects: 1205
Study 22769438 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-flap debridement (OFD)
Number of subjects: 60
Study 22769438 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-flap debridement in endodontically treated teeth (OFD + ET)
Number of subjects: 60
Study 21127273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sartorius muscle stimulation
Number of subjects: 72
Study 21127273 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps muscle stimulation
Number of subjects: 72
Study 18756943 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticles injection (either by endoscopic injection or intraoperative subserosal injection)
Number of subjects: 42
Study 18756943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activated carbon nanoparticles injection)
Number of subjects: 42
Study 18756943 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticles injection
Number of subjects: 42
Study 17043255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 80
Study 17043255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 80
Study 11814098 — intervention group
Group type: EXPERIMENTAL
Intervention: Quotidian hemodialysis
Number of subjects: 18
Study 11814098 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 18
Study 10037380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 1 month
Number of subjects: 40
Study 10037380 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 40
Study 7740908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam
Number of subjects: 102
Study 7740908 — intervention group
Group type: COMPARATOR
Intervention: Combination of meperidine 6.0 mg/mL, atropine 0.08 mg/mL, and diazepam 0.6 mg/mL (0.2 mL/kg)
Number of subjects: 102
Study 2251993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 235
Study 2251993 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulants (heparin followed by phenprocoumon)
Number of subjects: 235
Study 7248206 — intervention group
Group type: EXPERIMENTAL
Intervention: Role rehearsal and modelling
Number of subjects: 51
Study 7248206 — intervention group
Group type: COMPARATOR
Intervention: Guided discussion
Number of subjects: 51
Study 30810785 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) TKA
Number of subjects: 393
Study 30810785 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing (FB) TKA
Number of subjects: 393
Study 27538832 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and mobility training (BMT)
Number of subjects: 44
Study 27538832 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and mobility plus cognitive training (BMT + C)
Number of subjects: 44
Study 27538832 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 44
Study 26418274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin administration
Number of subjects: 45
Study 26418274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23233381 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed technique using NAV-rejected k-space lines
Number of subjects: 31
Study 23233381 — intervention group
Group type: COMPARATOR
Intervention: Conventional method using NAV-accepted lines
Number of subjects: 31
Study 23233381 — intervention group
Group type: COMPARATOR
Intervention: Simple averaging of all k-space lines
Number of subjects: 31
Study 23233381 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed technique for late gadolinium enhancement
Number of subjects: 31
Study 23233381 — intervention group
Group type: COMPARATOR
Intervention: Conventional method for late gadolinium enhancement
Number of subjects: 31
Study 23233381 — intervention group
Group type: COMPARATOR
Intervention: Simple averaging for late gadolinium enhancement
Number of subjects: 31
Study 21209033 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 5000
Study 21209033 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 5000
Study 19617841 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg wrapping with tight elastic bandage plus placebo intravenous injections
Number of subjects: 40
Study 19617841 — intervention group
Group type: COMPARATOR
Intervention: Repeated phenylephrine boluses of 50 microg plus loose placebo wrapping
Number of subjects: 40
Study 17179052 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg per kg of body weight) every 2 weeks for up to 35 months (median, 18.5 months)
Number of subjects: 82
Study 17179052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17179052 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg per kg of body weight) in protocol-adherent patients
Number of subjects: 82
Study 17179052 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg per kg of body weight) in patients with baseline eGFR > 55 mL/min per 1.73 m2
Number of subjects: 82
Study 17179052 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg per kg of body weight) in patients with baseline eGFR ≤ 55 mL/min per 1.73 m2
Number of subjects: 82
Study 17179052 — intervention group
Group type: COMPARATOR
Intervention: Agalsidase beta and Placebo
Number of subjects: 82
Study 15193468 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture media with 5% carbon dioxide
Number of subjects: 0
Study 15193468 — intervention group
Group type: COMPARATOR
Intervention: Culture media with 6% carbon dioxide
Number of subjects: 0
Study 11531899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 924
Study 11531899 — intervention group
Group type: EXPERIMENTAL
Intervention: Alniditan 1.4 mg
Number of subjects: 924
Study 11531899 — intervention group
Group type: EXPERIMENTAL
Intervention: Alniditan 1.8 mg
Number of subjects: 924
Study 11531899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg
Number of subjects: 924
Study 9471290 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine and prilocaine) applied before laser treatment
Number of subjects: 6
Study 9471290 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (control group)
Number of subjects: 6
Study 8509530 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage tilt test with an infusion of 5 micrograms/min of isoproterenol
Number of subjects: 40
Study 8509530 — intervention group
Group type: COMPARATOR
Intervention: Multistage tilt test with infusions of 0, 2 and 5 micrograms/min of isoproterenol
Number of subjects: 40
Study 8509530 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage tilt test
Number of subjects: 40
Study 8509530 — intervention group
Group type: COMPARATOR
Intervention: Multistage tilt test
Number of subjects: 40
Study 3543769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (4 g intravenously before surgery, second dose 4-6 hours later, final dose 6 hours after)
Number of subjects: 30
Study 3543769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, same dosing schedule as mezlocillin)
Number of subjects: 30
Study 31272592 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 52
Study 31272592 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 52
Study 27605214 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based health coaching
Number of subjects: 184
Study 27605214 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 26048382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (infused in addition to saline for 4 hours before and 24 hours after PCI)
Number of subjects: 213
Study 26048382 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 213
Study 26048382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 213
Study 23787458 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL) treatment
Number of subjects: 47
Study 23787458 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreated patients with keratoconus)
Number of subjects: 47
Study 23787458 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL treatment
Number of subjects: 47
Study 23787458 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 21490140 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish-oil capsules (≈800 mg DHA/d)
Number of subjects: 182
Study 21490140 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil capsules (control group)
Number of subjects: 182
Study 19190915 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe tricuspid AS
Number of subjects: 100
Study 19190915 — intervention group
Group type: COMPARATOR
Intervention: Controls (without valvular pathology)
Number of subjects: 100
Study 16763099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (Lo) at 39 +/- 3% peak oxygen consumption for 60 min
Number of subjects: 6
Study 16763099 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (Hi) at 83 +/- 2% peak oxygen consumption for 27 +/- 2 min
Number of subjects: 6
Study 16763099 — intervention group
Group type: COMPARATOR
Intervention: Both exercise intensities (Lo and Hi)
Number of subjects: 6
Study 15221297 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (TIMI flow 2-3)
Number of subjects: 36
Study 15221297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 15221297 — intervention group
Group type: COMPARATOR
Intervention: Group B (TIMI flow 0-1)
Number of subjects: 36
Study 10761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (isosorbide‐5‐mononitrate and propranolol or nadolol)
Number of subjects: 0
Study 10761206 — intervention group
Group type: COMPARATOR
Intervention: Propranolol or nadolol alone
Number of subjects: 0
Study 10761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 0
Study 10761206 — intervention group
Group type: COMPARATOR
Intervention: Emergency sclerotherapy
Number of subjects: 0
Study 10761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0
Study 10761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study 10761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy and endoscopic banding ligation
Number of subjects: 0
Study 10761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy followed by semi‐emergency endoscopic therapy
Number of subjects: 0
Study 10761206 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS or emergency surgery
Number of subjects: 0
Study 8383415 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg iron daily
Number of subjects: 43
Study 8383415 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron daily
Number of subjects: 43
Study 3532848 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled synthetic oligonucleotide probe
Number of subjects: 50
Study 2463726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40 (n = 16)
Number of subjects: 61
Study 2463726 — intervention group
Group type: COMPARATOR
Intervention: Acetated Ringer solution (n = 45)
Number of subjects: 61
Study 30830708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' empathy motivation scale (27 items) validated through psychometric evaluation
Number of subjects: 640
Study 27692023 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (150 ml with dinner)
Number of subjects: 65
Study 27692023 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (150 ml with dinner)
Number of subjects: 65
Study 25313213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin Cmax >8.2 mg/liter
Number of subjects: 54
Study 25313213 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide AUC/MIC >11.3
Number of subjects: 54
Study 25313213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin AUC <35.4 mg · h/liter
Number of subjects: 54
Study 25313213 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid Cmax
Number of subjects: 54
Study 25313213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol Cmax/MIC
Number of subjects: 54
Study 25313213 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting isoniazid
Number of subjects: 54
Study 25313213 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing rifampin, pyrazinamide, and ethambutol exposures
Number of subjects: 54
Study 24227358 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid and salt regimen
Number of subjects: 240
Study 24227358 — intervention group
Group type: COMPARATOR
Intervention: Liberal control fluid regimen
Number of subjects: 240
Study 22147842 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 2515
Study 22147842 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Number of subjects: 2515
Study 22147842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2515
Study 18923884 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTD20 (20 microg)
Number of subjects: 1637
Study 18923884 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTD40 (40 microg)
Number of subjects: 1637
Study 18923884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study 12772396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba 100 mg daily
Number of subjects: 24
Study 12772396 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 mg daily
Number of subjects: 24
Study 12772396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10884486 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWH)
Number of subjects: 3048
Study 9292184 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 128 micrograms once daily
Number of subjects: 635
Study 9292184 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 256 micrograms once daily
Number of subjects: 635
Study 9292184 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms once daily
Number of subjects: 635
Study 9292184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 8165608 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA and DHA)
Number of subjects: 20
Study 8165608 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 20
Study 3533454 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone high dosage (300 mg every eight hours)
Number of subjects: 12
Study 3533454 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone low dosage (150 mg every eight hours)
Number of subjects: 12
Study 3533454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28410250 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill training (20 mins/d, 3 d/wk) together with traditional physical therapy for 3 months
Number of subjects: 30
Study 28410250 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy program
Number of subjects: 30